At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.
Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
Illumina's acquisition of Grail, Exact Sciences' acquisition of Thrive Earlier Detection, and Invitae's acquisition of ArcherDx all topped out at over $1 billion.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
